Vitamin K (Fig. 1) , an essential nutrient, has an important role in normal blood coagulation systems from post-translational modification.
1) It acts as a cofactor of a number of plasma proteins such as prothrombin, factor VII, IX and X.
In recent years, several investigations have shown that vitamin K also possesses anticancer activity. 2, 3) The action mechanism was mentioned in two different fields. Hemostatic proteins, such as thrombin, fibrin and tissue factors, in fact, play dual roles in both thrombosis formation and cancer progression. 4, 5) On the other hand, Lamson and Plaza reviewed that vitamin K 3 (VK 3 ) directly inhibited cancer cell growth in vivo and in vitro, 3) causing growth inhibition of Hep G2 6) and Hep 3B 7) human hepatoblastoma. Several action theories have been proposed in the growth inhibitory and cytotoxic effects of VK 3 . Historically, the main effect is believed to be due to oxidative stress via redox cycling of the quinone to produce reactive oxygene species, 8, 9) while a lower concentration of VK 3 induces apoptosis by a non-oxidative mechanism. 10) In hepatocytes, VK 3 increases the level of p21
Cip1 , which induces the cell cycle to G 0 /G 1 arrest. 11) In addition, previous reports showed that several synthesized vitamin K analogs regulated the G 1 /S phase by antagonizing Cdc25A directly. [12] [13] [14] In therapeutic use, a lower dosage is required for practical applicability. For this reason, we evaluated the possibility of VK 3 in non-oxidative conditions in hepatic cancer cells. Our observations indicated that VK 3 -induced apoptosis intensity is insufficient for anticancer monotherapy; however, it has potential as a chemotherapeutic enhancer in combination with G 2 /M-selective topoisomerase II inhibitor.
MATERIALS AND METHODS

Cells and Reagents
Hep G2 human hepatoblastoma cells were maintained with Williams' E (WE) medium supplemented with 10% fetal bovine serum (FBS), 50 IU/ml penicillin G and 50 mg/ml streptomycin. Protein G-conjugated Sepharose 4B, irinotecan and etoposide were obtained from Sigma-Aldrich, Inc. (St. Louis, MO, U.S.A.). Peroxidase-conjugated anti-mouse IgG was purchased from Amersham Pharmacia Biotech (Arlington Heights, IL, U.S.A.). All other materials were purchased from Nacalai Tesque Inc. (Kyoto, Japan).
Evaluation of Growth Inhibitory Potential Cell Counting Kit-F (Dojindo Laboratories, Kumamoto, Japan) was used to assess cell viability. 15) Briefly, cells were seeded onto collagen-coated 96 well culture plates at a density of 1ϫ10 4 cells/well and incubated for 24 h. The cells were treated with VK 3 for a further 24 h. They were then washed with PBS and allowed to react with calcein-AM for 30 min. The released fluorescent calcein was measured in a CytoFluor ® Plate Reader (PerSeptive Biosystems, Foster City, CA, U.S.A.) using an excitation wavelength of 490 nm/emission 515 nm.
Flow Cytometry HepG2 was seeded onto collagencoated 100 mm cell culture dishes at a density of 1.5ϫ10 6 cells/dish and cultured for 24 h. They were then incubated with serum-starved WE for a further 24 h to synchronize the cell cycle to G 1 phase. The medium was then changed to FBS-containing WE and the cells were treated with VK 3 (3 to 30 mM) for 8 h, and subsequently incubated with 10 mM BrdU for 30 min. Trypsinized cells were collected by centrifugation (750 g, 10 min at 4°C) and fixed in ice-cold 70% ethanol overnight. They were resuspended in 0.1% Na 2 solution and allowed to stand for 2 min. After neutralization with hydrochloric acid, they were centrifuged and the pellet was reacted with FITC-conjugated anti-BrdU antibody (1/200 dilution with 0.5% Tween 20 in PBS) for 30 min, followed by propidium iodide (0.5 mg/ml) for 10 min under dark conditions. Flow cytometric profiles were determined with FACSCalibur analyzer and CELLQuest software (Becton Dickinson Immunocytometry Systems, Mountain View, CA, U.S.A.) at an excitation of 488 nm argon laser.
Detection of Cyclins and Cell Cycle-Dependent Kinases G 1 -arrested Hep G2 were incubated with VK 3 for 8 h as described above. They were harvested with lysis buffer (0.5% SDS, 1% Triton X-100, 150 mM NaCl, 5 mM EDTA, 1 mM Na 3 VO 4 , 10 mM Na 2 MnO 4 , 1 mM PMSF, 10 mM leupepin and 20 mM Tris; pH was adjusted at 7.5 with HCl). The lysate was then immunoprecipitated using anti-phosphotyrosine or anti-cyclins with protein G Sepharose 4B for 17 h at 4°C by conventional methods. Electrophoresis was performed on 12.5% T gel and the separated proteins were electrotransferred to the membrane at 150 mA for 1 h. After washing twice with TBST (0.1% Tween 20, 150 mM NaCl and 10 mM Tris-HCl, pH 7.4), the blots were blocked in 5% skim milk for 1 h. Next, each primary antibody against cyclin-dependent kinase (cdk, 1 : 500 dilution) was applied for 17 h at 4°C. After washing, peroxidase-conjugated anti-mouse IgG (1 : 5000 dilution) was treated for more 1 h, followed by the reaction of enhanced chemiluminescence (Amersham Pharmacia Biotech) to detect antigens.
Enhancement of Antitumor Agents
The cells were plated onto a collagen-coated 96 well plates and cultured for 24 h. After washing with PBS, they were treated with irinotecan or etoposide for a further 24 h in the presence of 5 mM VK 3 . Cell viability was assessed using Cell Counting Kit-F (Dojindo Laboratories, Kumamoto, Japan) as described above. The released fluorescent calcein was measured as a intracellular esterase.
Statistical Analysis In order to evaluate the cell population of each cell-cycle phase, Williams' multiple comparison followed by discriminant analysis was applied. Regarding the assessment of synergistic action between anticancer drus and VK 3 , data were analyzed through two-way analysis of variance (ANOVA). Results are expressed as meanϮS.D. and a p value of less than 0.05 was considered to indicate a statistically significant difference.
RESULTS
The authors first assessed the effect of VK 3 on the cell viability of Hep G2 using cytosolic esterase activity ( Fig.  2A) . VK 3 dose-dependently diminished the cell viability with IC 50 value of 13.7 mM. The Hill coefficient value was 3.1, and the concentration-dependent slope was steep. We next evaluated the effect of VK 3 on the cell cycle of Hep G2 human hepatoblastoma. As shown in Fig. 2B , VK 3 decreased the population of the S phase and arrested the cell cycle at the G 2 /M phase in a dose-dependent manner. G 2 /M arrest was displayed more clearly using discriminant analysis (Fig. 2C) .
Regulation of Cell Cycle by VK 3 To clarify the action mechanism of G 2 /M arrest, we next examined the activation of cyclin-dependent kinases (cdk). Multiple phosphorylated sites play an important role in both cdk activation and inactivation. Threonine phosphorylation in the T-loop, mediated by cdk-activating kinase, is essential for activation of the cyclin/cdk complex. 16, 17) On the other hand, the cyclin/cdk2 complex in the G 2 phase is downregulated by phosphorylation at Tyr15, which is situated in the ATP-binding site of cdk2. 18) Since VK 3 acts in G 2 /M arrest, we investigated the effect of VK 3 on tyrosine phosphorylation in cdks.
Eight hours after VK 3 addition, the cells were harvested and Tyr-phosphorylated cdks were detected by immunoblot analysis. Tyr-phosphorylated cdk1, 2 and 4 were detected in hepatocytes treated with VK 3 at 10 mM; however, phosphorylation was depressed at higher concentration in cdk2 and 4 (Fig. 3A) . Concomitantly with Tyr phosphorylation, cyclin B was gradually decreased and cyclin D was completely diminished by VK 3 treatment (Fig. 3B) . We further demonstrated the formation of cyclin/cdk complexes (Fig. 3C) . In VK 3 -treated hepatocytes, cyclin A/cdk1 and cyclin A/cdk2 complex dose-dependently increased, whereas the cyclin D/cdk4 and cyclin B/cdk1 complex was decreased. These findings indicate that VK 3 accelerates S phase turnover by the activation of cyclin A/cdk2 and induces G 2 /M arrest by the inhibition of cyclin B/cdk1 complex formation.
Enhancement of VK 3 on G 2 /M Phase-Dependent Chemotherapy Our findings suggest that VK 3 would be able to enhance G 2 /M phase-dependent anticancer drugs for hepatoma chemotherapy. To demonstrate this hypothesis, combined treatment of VK 3 and anticancer drugs was administered for Hep G2 hepatocytes. In the presence of 5 mM VK 3 , the cytotoxicity of etoposide, a G 2 phase-dependent agent, was synergistically enhanced, especially at higher concentrations (Fig. 4, right panel) . In contrast, VK 3 markedly reduced the cytotoxic activity of irinotecan, a S phase-dependent drug (left panel), at lower concentrations. These results indicated that VK 3 has potential as an enhancer of G 2 phase-dependent anticancer agents.
DISCUSSION
Our results indicate that VK 3 causes the dysfunction of Hep G2 cells by arresting the cell cycle in the G 2 /M phase. Regarding the potential for VK 3 monotherapy, the cytotoxicity (IC 50 of 13.7 mM) is not sufficient and additionally, it is hard to control the therapeutic range because of the steep gradient of the dose-dependent curve ( Fig. 2A) .
Since DNA is super-coiled, and tightly fitted in the chromosomes, the DNA-replication fork is unable to synthesize new DNA out of topological constrained DNA. Topoisomerase I relaxes the DNA molecules by binding to supercoiled DNA and cleaving a phosphodiester bond, resulting in a single-strand break. 19) Inhibitors of topoisomerase I, including irinotecan, breaks may lead to cell cycle arrest in the S/G 2 phase and thus they are much more sensitive to S-phase synchronized cells. 20, 21) On the other hand, topoisomerase II causes reversible double-strand DNA cleavage with the relaxation of DNA. 22) It regulates over-and under-winding of the double helix and resolves nucleic acid knots and tangles. Topoisomerase II inhibitors, including etoposide, increase the steady-state concentration of their covalent DNA cleavage complexes. 22, 23) For these reasons, etoposide induces cell cycle arrest in the G 2 /M phase and apoptosis in a p53-related manner. 24) Our observations revealed that VK 3 accelerated S-phase turnover by the activation of cyclin A/cdk2 and induced G 2 /M arrest by the inhibition of cyclin B/cdk1 complex formation (Fig. 3C) . As a result, G 2 /M-phase synchronized cells were accumulated and the cells were more sensitive to G 2 /Mselective topoisomerase II inhibitor etoposide, as descrived above (Fig. 4) . In contrast, the cells were less sensitive to irinotecan by the acceleration of S-phase turnover.
In conclusion, these results suggest the possibility of VK 3 as a chemotherapic enhancer in combination with topoisomerase II inhibitors. To evaluate the effects of the VK 3 combination with chemotherapeutic agents in detail, dose-response curves is not always suitable. 25) Further isobologram analyses are needed to clarify the VK 3 role is whether "additive" or "synergic". 26, 27) 
